Developer docs
API playgroundTry for free, no card

Search company profiles

NextPharma

Full company profile

uuid0009fts

Namestring
NextPharma
Legal namestring
NextPharma Technologies
Websiteurl
nextpharma.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

NextPharma is a European pharmaceutical contract development and manufacturing organization (CDMO) headquartered in London and operating 10 manufacturing centres of excellence across the United Kingdom, France, Germany, Finland, and Norway. The company offers five core service lines — Pharmaceutical Development, Clinical Trials Services, Commercial Manufacturing & Packaging, Health & Nutrition, and Analytical & Microbiological Services — delivering across a broad range of dosage forms including softgel and liquid-filled hard capsules (Licaps), lipid-based formulations, tablets, liquids, suppositories, cephalosporins, penicillins, hormones, ophthalmics, and chewable tablets. Aggregated disclosed capacity is in the multi-billion unit range (e.g., ~4 billion tablets/year at Göttingen Solids, ~3.9 billion softgel capsules/year at Ploërmel, 3 million litres/year liquids at Limay).

Short descriptiontext

NextPharma is a Europe-based pharmaceutical CDMO operating 10 manufacturing centres of excellence across the UK, France, Germany, Finland, and Norway, offering development, clinical trials supply, commercial manufacturing, and analytical services across a wide range of dosage forms to pharma, biotech, and nutraceutical companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices11 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical contract manufacturing, drug development services, clinical trials supply, softgel manufacturing, oral dosage forms CDMO
Industry4 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Contract Manufacturing (CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Manufacturing Services
TypeProfessional Services
Description

Revenue generated from providing pharmaceutical development and manufacturing services to pharmaceutical, biotech, and nutraceutical companies under contract manufacturing agreements

nextpharma.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Licaps
Description

Licaps technology for pharmaceutical products - liquid-filled hard capsules for OTC and Rx products

nextpharma.com
Core offering1 text field

NextPharma is a European pharmaceutical Contract Development and Manufacturing Organisation (CDMO) that provides formulation development, clinical trial supply, commercial manufacturing, and packaging of solid, liquid, semi-solid, and specialised dosage forms (including softgels, tablets, suppositories, cephalosporins, penicillins, hormones, and ophthalmics) for pharmaceutical, biotech, and nutraceutical customers. Services are delivered through 10 specialised centres of excellence across the UK, France, Germany, Finland, and Norway under GMP conditions with EMA, US FDA, and ANVISA regulatory approvals.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

NextPharma is a Contract Development and Manufacturing Organization (CDMO) offering integrated pharmaceutical development and manufacturing services across Europe. The company operates as a platform of specialized sites rather than a single product, providing five core services: Pharmaceutical Development (formulation and technical transfer), Clinical Trials Services (supply chain for trials), Commercial Manufacturing & Packaging (solid, liquid, and semi-solid dosage forms), Health and Nutrition (food supplements and softgels), and Analytical and Microbiological Services (quality control and stability testing). These services are delivered through a network of nine manufacturing centres of excellence across Europe, including specialized facilities for lipid-based formulations and softgels in Ploërmel (France), liquids and suppositories in Limay (France), cephalosporins and solids in Göttingen (Germany), and additional sites for penicillins, modified release, hormones, ophthalmics, and chewable tablets.

Product and service5 records
1Pharmaceutical Development
CategoryPharmaceutical Development Services
Description

Contract development services supporting drug development projects from early stages through manufacturing, including formulation development and technical transfer for pharmaceutical and biotech customers.

2Clinical Trials Services
CategoryClinical Trial Supply Services
Description

Flexible clinical trial supply services including manufacturing, packaging, and distribution for clinical trial programs, provided from the Göttingen Solids & CTS centre of excellence.

3Commercial Manufacturing & Packaging
CategoryCommercial Contract Manufacturing
Description

Contract manufacturing and packaging services across multiple dosage forms including tablets, capsules, liquids, suppositories, and specialty forms, supporting commercial supply requirements for pharma and biotech customers.

4Health & Nutrition
CategoryNutraceutical Contract Manufacturing
Description

European contract development and manufacturing partner for food supplements, providing nutritional solutions and softgel manufacturing for nutraceutical companies.

5Analytical & Microbiological Services
CategoryAnalytical and Quality Control Services
Description

Analytical and microbiological testing services to support product development, quality control, and stability studies, offered as a CDMO service.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-10-13
Description

NextPharma sold its logistics arm to Cencora as part of a strategic repositioning to become Europe's leading pure-play CDMO. The transaction was announced on October 13, 2025, and completed as part of NextPharma's strategy to focus on core pharmaceutical development and manufacturing services.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-06
Description

NextPharma partnered with Takeda to acquire the pharmaceutical manufacturing site in Asker, Norway, announced in September 2022 and completed in April 2023. This acquisition expanded NextPharma's chewable tablets capabilities and established a centre of excellence in Norway.

Strategic tierCoreTypeOthersAnnounced on2021-04-01
Description

NextPharma completed acquisition of two Lonza sites specialized in lipid oral dosage forms in April 2021, including the Ploërmel site in France, significantly expanding softgel and lipid-based formulation capabilities.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global pure-play CDMO with deep softgel, oral solid and sterile fill-finish capabilities. Direct competitor in lipid-based formulations and oral dose; multiple NextPharma senior leaders (CCO, COO) joined from Catalent.

TypeDirect peer
Description

Germany-headquartered CDMO focused on solid and semi-solid dosage forms, including softgels. Closest geographic and capability peer to NextPharma, with overlapping European customer base in pharma and nutraceuticals.

3Recipharm
TypeDirect peer
Description

Swedish CDMO offering development, manufacturing and clinical supply services across multiple dosage forms. Comparable European platform with similar mix of acquired legacy pharma sites and a focus on oral solids, semi-solids and injectables.

TypeDirect peer
Description

France-based CDMO with a broad European network of manufacturing sites serving pharma clients on solid, liquid and sterile forms. Direct competitor for French and pan-European contract manufacturing opportunities.

5Fareva
TypeDirect peer
Description

French private CDMO with extensive European manufacturing footprint across pharmaceutical, cosmetic and specialty dosage forms. Comparable business model as a multi-site European contract manufacturer serving big pharma.

TypeDirect peer
Description

Full-service CDMO with strong capabilities in oral solid dose, sterile injectables, peptides and highly potent APIs. Direct competitor; NextPharma's COO previously served as Managing Director of Corden Pharma GmbH.

TypeDirect peer
Description

Swiss-listed CDMO with European and US sites covering small-molecule API and finished dose manufacturing. Comparable platform of acquired legacy pharma sites, similar customer base in branded and generic pharmaceuticals.

TypeBroad incumbent
Description

Global CDMO division of Thermo Fisher offering a full spectrum of development, clinical and commercial manufacturing services. Not a pure-play CDMO; overlaps with NextPharma in oral solid dose, softgels and clinical supply but operates at materially larger scale.

TypeDirect peer
Description

Portuguese CDMO specialising in API development, particle engineering and oral/inhalation dosage forms. Comparable in scale and customer mix, with overlapping expertise in complex small-molecule formulations.

TypeBroad incumbent
Description

Global CDMO leader with capabilities spanning small molecules, biologics and cell & gene therapies. Sold its lipid/softgel Ploërmel site to NextPharma in 2021, making Lonza a former owner of a key NextPharma asset as well as a broader-sector competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries11 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance14 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NextPharma

Pharmaceutical Contract Manufacturing (CDMO)nextpharma.com

NextPharma is a Europe-based pharmaceutical CDMO operating 10 manufacturing centres of excellence across the UK, France, Germany, Finland, and Norway, offering development, clinical trials supply, commercial manufacturing, and analytical services across a wide range of dosage forms to pharma, biotech, and nutraceutical companies.

What NextPharma does

NextPharma is a European pharmaceutical contract development and manufacturing organization (CDMO) headquartered in London and operating 10 manufacturing centres of excellence across the United Kingdom, France, Germany, Finland, and Norway. The company offers five core service lines — Pharmaceutical Development, Clinical Trials Services, Commercial Manufacturing & Packaging, Health & Nutrition, and Analytical & Microbiological Services — delivering across a broad range of dosage forms including softgel and liquid-filled hard capsules (Licaps), lipid-based formulations, tablets, liquids, suppositories, cephalosporins, penicillins, hormones, ophthalmics, and chewable tablets. Aggregated disclosed capacity is in the multi-billion unit range (e.g., ~4 billion tablets/year at Göttingen Solids, ~3.9 billion softgel capsules/year at Ploërmel, 3 million litres/year liquids at Limay).

NextPharma firmographics

Firmographics
Name
NextPharma
Legal name
NextPharma Technologies
Website
https://nextpharma.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
NextPharma is a Europe-based pharmaceutical CDMO operating 10 manufacturing centres of excellence across the UK, France, Germany, Finland, and Norway, offering development, clinical trials supply, commercial manufacturing, and analytical services across a wide range of dosage forms to pharma, biotech, and nutraceutical companies.
Ownership category
akta.pro rank

NextPharma industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Pharmaceutical contract manufacturing
  • Drug development services
  • Clinical trials supply
  • Softgel manufacturing
  • Oral dosage forms CDMO

Where NextPharma is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices11 records

Markets served

NextPharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Manufacturing Services: Revenue generated from providing pharmaceutical development and manufacturing services to pharmaceutical, biotech, and nutraceutical companies under contract manufacturing agreements

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

NextPharma product offering

Product offering

Core offering

NextPharma is a European pharmaceutical Contract Development and Manufacturing Organisation (CDMO) that provides formulation development, clinical trial supply, commercial manufacturing, and packaging of solid, liquid, semi-solid, and specialised dosage forms (including softgels, tablets, suppositories, cephalosporins, penicillins, hormones, and ophthalmics) for pharmaceutical, biotech, and nutraceutical customers. Services are delivered through 10 specialised centres of excellence across the UK, France, Germany, Finland, and Norway under GMP conditions with EMA, US FDA, and ANVISA regulatory approvals.

Product overview

NextPharma is a Contract Development and Manufacturing Organization (CDMO) offering integrated pharmaceutical development and manufacturing services across Europe. The company operates as a platform of specialized sites rather than a single product, providing five core services: Pharmaceutical Development (formulation and technical transfer), Clinical Trials Services (supply chain for trials), Commercial Manufacturing & Packaging (solid, liquid, and semi-solid dosage forms), Health and Nutrition (food supplements and softgels), and Analytical and Microbiological Services (quality control and stability testing). These services are delivered through a network of nine manufacturing centres of excellence across Europe, including specialized facilities for lipid-based formulations and softgels in Ploërmel (France), liquids and suppositories in Limay (France), cephalosporins and solids in Göttingen (Germany), and additional sites for penicillins, modified release, hormones, ophthalmics, and chewable tablets.

Differentiator

Problem solved

Functional benefit

Brands

  • Licaps: Licaps technology for pharmaceutical products - liquid-filled hard capsules for OTC and Rx products

Products and services

  • Pharmaceutical Development Contract development services supporting drug development projects from early stages through manufacturing, including formulation development and technical transfer for pharmaceutical and biotech customers.
  • Clinical Trials Services Flexible clinical trial supply services including manufacturing, packaging, and distribution for clinical trial programs, provided from the Göttingen Solids & CTS centre of excellence.
  • Commercial Manufacturing & Packaging Contract manufacturing and packaging services across multiple dosage forms including tablets, capsules, liquids, suppositories, and specialty forms, supporting commercial supply requirements for pharma and biotech customers.
  • Health & Nutrition European contract development and manufacturing partner for food supplements, providing nutritional solutions and softgel manufacturing for nutraceutical companies.
  • Analytical & Microbiological Services Analytical and microbiological testing services to support product development, quality control, and stability studies, offered as a CDMO service.

Companies that use NextPharma

Customer profile

Segments2 records

Ideal customer profiles2 records

NextPharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

NextPharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered major and core.

  • CencoramajorStrategic or Co-development Partner · 13 October 2025NextPharma sold its logistics arm to Cencora as part of a strategic repositioning to become Europe's leading pure-play CDMO. The transaction was announced on October 13, 2025, and completed as part of NextPharma's strategy to focus on core pharmaceutical development and manufacturing services.
  • TakedacoreStrategic or Co-development Partner · 6 September 2022NextPharma partnered with Takeda to acquire the pharmaceutical manufacturing site in Asker, Norway, announced in September 2022 and completed in April 2023. This acquisition expanded NextPharma's chewable tablets capabilities and established a centre of excellence in Norway.
  • LonzacoreOthers · 1 April 2021NextPharma completed acquisition of two Lonza sites specialized in lipid oral dosage forms in April 2021, including the Ploërmel site in France, significantly expanding softgel and lipid-based formulation capabilities.

Scale indicators10 records

Recent moves7 records

Expansion highlights4 records

NextPharma competitors and assessment

Company assessment

Direct peers

  • Catalent: Global pure-play CDMO with deep softgel, oral solid and sterile fill-finish capabilities. Direct competitor in lipid-based formulations and oral dose; multiple NextPharma senior leaders (CCO, COO) joined from Catalent.
  • Aenova Group: Germany-headquartered CDMO focused on solid and semi-solid dosage forms, including softgels. Closest geographic and capability peer to NextPharma, with overlapping European customer base in pharma and nutraceuticals.
  • Recipharm: Swedish CDMO offering development, manufacturing and clinical supply services across multiple dosage forms. Comparable European platform with similar mix of acquired legacy pharma sites and a focus on oral solids, semi-solids and injectables.
  • Delpharm: France-based CDMO with a broad European network of manufacturing sites serving pharma clients on solid, liquid and sterile forms. Direct competitor for French and pan-European contract manufacturing opportunities.
  • Fareva: French private CDMO with extensive European manufacturing footprint across pharmaceutical, cosmetic and specialty dosage forms. Comparable business model as a multi-site European contract manufacturer serving big pharma.
  • Corden Pharma: Full-service CDMO with strong capabilities in oral solid dose, sterile injectables, peptides and highly potent APIs. Direct competitor; NextPharma's COO previously served as Managing Director of Corden Pharma GmbH.
  • Siegfried Holding: Swiss-listed CDMO with European and US sites covering small-molecule API and finished dose manufacturing. Comparable platform of acquired legacy pharma sites, similar customer base in branded and generic pharmaceuticals.
  • Hovione: Portuguese CDMO specialising in API development, particle engineering and oral/inhalation dosage forms. Comparable in scale and customer mix, with overlapping expertise in complex small-molecule formulations.

Broad incumbents

  • Thermo Fisher Scientific (Patheon): Global CDMO division of Thermo Fisher offering a full spectrum of development, clinical and commercial manufacturing services. Not a pure-play CDMO; overlaps with NextPharma in oral solid dose, softgels and clinical supply but operates at materially larger scale.
  • Lonza: Global CDMO leader with capabilities spanning small molecules, biologics and cell & gene therapies. Sold its lipid/softgel Ploërmel site to NextPharma in 2021, making Lonza a former owner of a key NextPharma asset as well as a broader-sector competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

NextPharma social profiles

Digital presence

NextPharma compliance and trust

Trust signal

Compliance14 records

NextPharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NextPharma leadership team

Management profile

Number of profiles

Profiles9 records

NextPharma subsidiaries and ownership

Company hierarchy

Subsidiaries11 records

NextPharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NextPharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NextPharma

What does NextPharma do?

NextPharma is a European pharmaceutical Contract Development and Manufacturing Organisation (CDMO) that provides formulation development, clinical trial supply, commercial manufacturing, and packaging of solid, liquid, semi-solid, and specialised dosage forms (including softgels, tablets, suppositories, cephalosporins, penicillins, hormones, and ophthalmics) for pharmaceutical, biotech, and nutraceutical customers. Services are delivered through 10 specialised centres of excellence across the UK, France, Germany, Finland, and Norway under GMP conditions with EMA, US FDA, and ANVISA regulatory approvals.

Is NextPharma a public or private company?

NextPharma is a private company. It is classified as private equity controlled and is currently operating.

When was NextPharma founded?

NextPharma was founded in 2021. It employs 1,001 to 5,000 people.

Where is NextPharma based?

NextPharma is headquartered in London, United Kingdom, in the Europe region.

How does NextPharma make money?

One revenue line is on record: contract Manufacturing Services.

Who are NextPharma's main competitors?

Direct peers on record are Catalent, Aenova Group, Recipharm, Delpharm, Fareva, Corden Pharma, Siegfried Holding and Hovione. Broad incumbents are Thermo Fisher Scientific (Patheon) and Lonza.

Does NextPharma have an API?

No public API is recorded for NextPharma.

What industry is NextPharma in?

NextPharma's product category is Pharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
HrtodayMonica Mauri Joins NextPharma as Chief People OfficerNextPharma has appointed Monica Mauri as its new Chief People Officer to strengthen its executive leadership and shape the company's HR vision. Mauri brings over three decades of experience in human resources and organizational transformation, previously serving as CHRO at ERIKS and holding senior roles at Staples Solutions and Randstad. This appointment supports NextPharma's ongoing development of its European pharmaceutical manufacturing and development platform.Nextpharma-LogisticsNextPharma verkauft Logistiksparte an Cencora › NextPharma LogisticsNextPharma has agreed to sell its healthcare logistics business, NextPharma Logistics GmbH, to Cencora, Inc. as part of its strategy to become Europe's leading contract development and manufacturing organization (CDMO). The transaction, expected to close in Q4 2025 pending regulatory approvals, involves approximately 230 employees providing pre-wholesale and logistics services from Germany, Austria, and Switzerland. NextPharma identified the logistics business as non-core to its focus on commercial manufacturing and product development, while the company continues investing in its CDMO capabilities, including recent expansions at facilities in France and Finland.MarketScreenerCencora, Inc. entered into an agreement to acquire Nextpharma Logistics GmbH from NextPharma GmbH.Cencora, Inc. entered into a definitive agreement on October 13, 2025, to acquire Nextpharma Logistics GmbH from NextPharma GmbH. The transaction remains subject to customary regulatory approvals and is anticipated to close in the fourth quarter of 2025. Legal advisors Philipp Pütz and Christian Ruoff of Freshfields represented Cencora in the deal.IspePharma 4.0™: Case Studies and Lessons LearnedISPE announced a conference track, "Pharma 4.0: Case Studies and Lessons Learned," at its 2024 Pharma 4.0 and Annex 1 Conference in Rome, 10-11 December, featuring industry case studies on digital transformation. Presentations cover Takeda's corporate data platform, Roche's cloud-based data hub, Next Pharma's operations platform, Merck's modular equipment connectivity, Bayer's AI screening, and Novo Nordisk's batch release.PR NewswireGlobal Drug Taste Masking and Taste Assessment Services and Technologies Market Report 2022: Oral Solid Dosage Market is the Largest Segment, Anticipated to Reach Over $900 Billion by 2027The report discusses the global taste masking and taste assessment services and technologies market, highlighting its development within the pharmaceutical industry, especially in oral solid dosage forms. It emphasizes the challenges in masking unpleasant tastes of active pharmaceutical ingredients (APIs) and the shift towards outsourcing these services to specialized providers. The market is projected to grow due to efforts to improve patient compliance and advances in taste-masking technologies.ContractpharmaNextPharma Completes Acquisition of Santen’s Tampere Manufacturing FacilityNextPharma completed its acquisition of Santen's Tampere, Finland ophthalmic manufacturing facility on September 30, 2019. The fully staffed site includes about 180 employees in manufacturing and support functions, who now work for NextPharma Oy. Most Santen Finland employees in sales, R&D, and other functions remain unaffected.